BlackRock Group’s Parnell Pharmaceuticals Holdings Ltd PARN Stock Holding History

BlackRock Group’s Portfolio PARN Stock Details PARN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$144K	Sell	209,120 -26,276	-11%	-$31.3K	﹤0.01%	2753
2016 Q3	$334K	Buy	235,396 +18,200	+8%	+$28.2K	﹤0.01%	2450
2016 Q2	$354K	Buy	217,196 +5,200	+2%	+$9.56K	﹤0.01%	2382
2016 Q1	$452K	Sell	211,996 -18,312	-8%	-$50.5K	﹤0.01%	2279
2015 Q4	$894K	Hold	230,308	–	–	﹤0.01%	1958
2015 Q3	$792K	Buy	230,308 +5,017	+2%	+$21.3K	﹤0.01%	2014
2015 Q2	$1.11M	Sell	225,291 -28,198	-11%	-$124K	﹤0.01%	1899
2015 Q1	$1.25M	Sell	253,489 -5,800	-2%	-$26.8K	﹤0.01%	1751
2014 Q4	$1.08M	Sell	259,289 -17,461	-6%	-$79.3K	﹤0.01%	1837
2014 Q3	$1.59M	Buy	+276,750	New	+$1.67M	﹤0.01%	1526

Other funds holding PARN

BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return

ECM

Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BIM

BlackRock Investment Management Wilmington, Delaware $86.4B AUM 16.83% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

VKH

Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock Group's PARN Position: Q4 2016 in Review

BlackRock Group reduced its Parnell Pharmaceuticals Holdings Ltd (PARN) stake by 11% in Q4 2016, selling an estimated $31.3K and leaving 209,120 shares worth $144K. The position accounts for ﹤0.01% of the portfolio, ranked #2753.

BlackRock Group first reported a position in PARN in Q3 2014 and has held it in 10 quarters since. The position peaked at $1.59M in Q3 2014. 20 funds tracked by Wall St. Rank hold PARN as of Q4 2016.

BlackRock Group held 209,120 shares of Parnell Pharmaceuticals Holdings Ltd worth $144K as of Q4 2016.
BlackRock Group sold 26,276 Parnell Pharmaceuticals Holdings Ltd shares in Q4 2016, an estimated $31.3K.
Parnell Pharmaceuticals Holdings Ltd made up ﹤0.01% of BlackRock Group's portfolio in Q4 2016, its #2753 holding.
BlackRock Group first reported a position in Parnell Pharmaceuticals Holdings Ltd in Q3 2014 and has held it in 10 quarters since.
BlackRock Group's Parnell Pharmaceuticals Holdings Ltd position peaked at $1.59M in Q3 2014.
20 funds tracked by Wall St. Rank held Parnell Pharmaceuticals Holdings Ltd as of Q4 2016.

Based on BlackRock Group's 13F filing for Q4 2016, filed 10 Feb 2017.